Parkinson's Disease
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All participants: - Written informed consent Study group: - Diagnosed Parkinson*s disease according to the UK Parkinson*s Disease Society Brain Bank Criteria Control group: - Healthy sex- and age-matched controls, also matched according to presence and severity of constipation.
Exclusion criteria
Exclusion criteria: All participants: Gastrointestinal exclusion criteria: - Active or persistent primary disease of the gastrointestinal tract - History of peritonitis, severe endometriosis, abdominal, intestinal or urogenital fistula, - Hepatobiliar or pancreatic disease (except asymptomatic cholecystolithiasis) - History of abdominal or anorectal surgery, except minor surgery such as uncomplicated appendectomy or cholecystectomy (>6 months ago) - Severe gynaecological prolapse (grade III) - Cancer and/or adjuvant treatment within the last 6 months - Within the last three months: narcosis, analgosedation, endoscopic procedure of the gastrointestinal tract, abdominal trauma - Within the last three months: gastrointestinal tract infection, food intoxication, Study group: - History of dopaminergic medication use Control group: - History of neurodegenerative disease, in particular signs of parkinsonism. - Probable prodromal PD. Controls will, however, be matched according to presence and severity of constipation as a possible confounder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Taxonomic classification of fecal microbiota composition through high-throughput sequencing and analysis of the 16S ribosomal RNA gene or metagenomic shotgun sequencing. At a later stage the gut microbiota of left over material can be assessed using other -omics methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome parameters include the presence and extend of (prodromal) PD symptomatology, specific treatment protocols and possible confounders influencing microbiota composition, including clinical-genetic PD subtypes, colon transit time, systemic inflammation and intestinal wall permeability. | — |
Countries
Netherlands
Outcome results
None listed